WAM
PTGX icon

Weiss Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Weiss Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.03M Buy
+9,780
New +$866K 0.02% 327
2025
Q4 		– Sell
-14,310
Closed -$951K – 795
2025
Q3 		$951K Buy
+14,310
New +$813K 0.01% 361
2024
Q4 		– Sell
-62,463
Closed -$2.81M – 824
2024
Q3 		$2.81M Buy
+62,463
New +$2.52M 0.06% 279

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Weiss Asset Management's PTGX Position: Q1 2026 in Review

Weiss Asset Management opened a new position in Protagonist Therapeutics (PTGX) in Q1 2026: 9,780 shares worth $1.03M. The stake represents 0.02% of the portfolio and ranks #327 among its holdings. This is a return to the name: Weiss Asset Management previously reported a position in PTGX as recently as Q3 2025.

Weiss Asset Management first reported a position in PTGX in Q3 2024 and has held it in 3 quarters since. The position peaked at $2.81M in Q3 2024. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Weiss Asset Management held 9,780 shares of Protagonist Therapeutics worth $1.03M as of Q1 2026.
  • Protagonist Therapeutics was a new Weiss Asset Management position in Q1 2026.
  • Protagonist Therapeutics made up 0.02% of Weiss Asset Management's portfolio in Q1 2026, its #327 holding.
  • Weiss Asset Management first reported a position in Protagonist Therapeutics in Q3 2024 and has held it in 3 quarters since.
  • Weiss Asset Management's Protagonist Therapeutics position peaked at $2.81M in Q3 2024.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Weiss Asset Management's 13F filing for Q1 2026, filed 15 May 2026.